



THESE FINANCIAL STATEMENTS FOR JUSHI HOLDINGS INC. ARE ALSO INCLUDED IN THE FORM 10-Q FOR
THE QUARTERLY PERIOD ENDED JUNE 30, 2026, FILED ON SEDAR IN ITS ENTIRETY

JUSHI HOLDINGS INC.

Table of Contents

For the quarterly period ended June 30, 2026

Part I	FINANCIAL INFORMATION	Page
Item 1	Financial Statements	
	Condensed Consolidated Balance Sheets	1
	Unaudited Condensed Consolidated Statements of Operations	2
	Unaudited Condensed Consolidated Statements of Changes in Equity (Deficit)	3
	Unaudited Condensed Consolidated Statements of Cash Flows	4
	Notes to the Unaudited Condensed Consolidated Financial Statements	6

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (this “report”) may contain “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws, including Canadian securities legislation and United States (“U.S.”) securities legislation (collectively, “forward-looking information”) which are based upon the Company’s current internal expectations, estimates, projections, assumptions and beliefs. All information, other than statements of historical facts, included in this report that address activities, events or developments that the Company expects or anticipates will or may occur in the future constitutes forward-looking information. Forward-looking information is often identified by the words, “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes, among others, information regarding: future business strategy; competitive strengths, goals, expansion and growth of the Company’s business, operations and plans, including new revenue streams; the refinancing or securing other sources of liquidity to meet debt repayment obligations; the integration and benefits of recently acquired businesses or assets; roll out of new operations; the implementation by the Company of certain product lines; the implementation of certain research and development; the application for additional licenses and the grant of licenses that will be or have been applied for; the expansion or construction of certain facilities; the reduction in the number of our employees; the expansion into additional U.S. and international markets; any potential future legalization of adult use and/or medical marijuana under U.S. federal law; expectations of market size and growth in the U.S. and the states in which the Company operates; expectations for other economic, business, regulatory and/or competitive factors related to the Company or the cannabis industry generally; and other events or conditions that may occur in the future.

Readers are cautioned that forward-looking information is not based on historical facts but instead is based on reasonable assumptions and estimates of the management of the Company at the time they were provided or made and such information involves known and unknown risks, uncertainties, including our ability to continue as a going concern, and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as applicable, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others: the benefits and timeline for consummating the Continuance; the limited operating history of the industry and the Company; risks related to managing the growth of the Company including completed, pending or future acquisitions or dispositions, including potential future impairment of goodwill or intangibles acquired and/or post-closing disputes; risks related to the continued performance, expansion and/or optimization of existing operations; risks related to capitalizing on Virginia's transition to an adult-use cannabis market; risks related to the anticipated openings of additional dispensaries or relocation of existing dispensaries subject to licensing approval; the Company’s historical operating losses and negative operating cash flows; increasing competition in the industry; risks inherent in an agricultural business, such as the effects of natural disasters; reliance on the expertise and judgment of senior management of the Company; risks associated with cannabis products manufactured for human consumption including potential product recalls; limited research and data relating to cannabis; constraints on marketing products; risk of litigation; insurance-related risks; public opinion and perception of the cannabis industry; risks related to the economy generally; fraudulent activity by employees, contractors and consultants; risks relating to the Company’s current amount of indebtedness; risks related to not being able to reduce or refinance its debt obligations; risks related to litigation or other disputes; reliance on key inputs, suppliers and skilled labor, and third party service provider contracts; reliance on manufacturers and contractors; risks of supply shortages or supply chain disruptions; risks relating to pandemics and forces of nature; risks related to the enforceability of contracts; risks related to inflation, the rising cost of capital, and stock market instability; risks relating to U.S. regulatory landscape and enforcement related to cannabis, including political risks; risks relating to anti-money laundering laws and regulation; cannabis-related tax risks and challenges from governmental authorities with respect to the Company’s application for Employee Retention Tax Credits (ERTC); other governmental and environmental regulation; risks related to proprietary intellectual property and potential infringement by third parties; sales of a significant amount of shares by existing shareholders; the limited market for securities of the Company; risks relating to the need to raise additional capital either through debt or equity financing; costs associated with the Company being a publicly-traded company and a U.S. and Canadian filer; risks related to co-investment with parties with different interests to the Company; conflicts of interest and related party transactions; cybersecurity risks; and risks related to the Company’s critical accounting policies and estimates. Refer to Part I - Item 1A. Risk Factors in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 31, 2026, for more information.

Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information will prove to be accurate as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on the forward-looking information contained in this report or other forward-looking statements made by the Company. Forward-looking information is provided and made as of the date of this Quarterly Report on Form 10-Q and the Company does not undertake any obligation to revise or update any forward-looking information or statements other than as required by applicable law.

Unless the context requires otherwise, references in this report to “Jushi,” “Company,” “we,” “us” and “our” refer to Jushi Holdings Inc. and our subsidiaries.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

JUSHI HOLDINGS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands of U.S. dollars, except share amounts)

	June 30, 2026 (unaudited)	December 31, 2025
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 33,329	\$ 24,047
Accounts receivable, net	4,191	2,801
Inventories, net	34,299	34,607
Prepaid expenses and other current assets	5,354	6,858
Total current assets	77,173	68,313
NON-CURRENT ASSETS:		
Property, plant and equipment, net	137,177	143,321
Right-of-use assets - finance leases	55,091	57,667
Other intangible assets, net	90,543	92,205
Goodwill	30,910	30,910
Other non-current assets	36,779	27,801
Restricted cash - non-current	2,125	2,125
Total non-current assets	352,625	354,029
Total assets	\$ 429,798	\$ 422,342
LIABILITIES AND EQUITY (DEFICIT)		
CURRENT LIABILITIES:		
Accounts payable	\$ 22,569	\$ 22,330
Accrued expenses and other current liabilities	25,905	25,531
Income tax payable	125	265
Debt, net - current portion	33,623	6,639
Finance lease obligations - current	10,941	11,125
Derivative liabilities - current	11	296
Total current liabilities	93,174	66,186
NON-CURRENT LIABILITIES:		
Debt, net - non-current (including related party principal amounts of \$49,009 and \$41,109 as of June 30, 2026 and December 31, 2025, respectively)	196,376	199,195
Finance lease obligations - non-current	52,959	53,547
Derivative liabilities - non-current	5,951	8,311
Unrecognized tax benefits (including interest and penalties of \$45,233 and \$38,342 as of June 30, 2026 and December 31, 2025, respectively)	193,946	177,242
Other liabilities - non-current	29,208	33,205
Total non-current liabilities	478,440	471,500
Total liabilities	571,614	537,686
COMMITMENTS AND CONTINGENCIES (Note 16)		
EQUITY (DEFICIT):		
Common stock, no par value; authorized shares - unlimited; issued and outstanding shares - 199,698,263 and 199,696,597 Subordinate Voting Shares as of June 30, 2026 and December 31, 2025, respectively	—	—
Paid-in capital	512,572	511,868
Accumulated deficit	(654,388)	(627,212)
Total deficit	(141,816)	(115,344)
Total liabilities and equity (deficit)	\$ 429,798	\$ 422,342

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

JUSHI HOLDINGS INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands of U.S. dollars, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
REVENUE, NET	\$ 71,297	\$ 65,046	\$ 137,729	\$ 128,892
COST OF GOODS SOLD	(39,767)	(36,122)	(76,322)	(74,193)
GROSS PROFIT	31,530	28,924	61,407	54,699
OPERATING EXPENSES				
Selling, general and administrative	29,314	28,746	57,719	56,266
Impairment and other asset-related gains/losses, net	1,502	(3,424)	1,391	(3,298)
Total operating expenses	30,816	25,322	59,110	52,968
INCOME FROM OPERATIONS	714	3,602	2,297	1,731
OTHER INCOME (EXPENSE):				
Interest expense, net	(9,886)	(10,219)	(20,274)	(20,219)
Fair value gain (loss) on derivatives	333	(187)	2,645	450
Other, net	534	4,401	(4,103)	7,598
Total other income (expense), net	(9,019)	(6,005)	(21,732)	(12,171)
LOSS BEFORE INCOME TAX	(8,305)	(2,403)	(19,435)	(10,440)
Income tax benefit (expense)	976	(9,928)	(7,741)	(18,906)
NET LOSS	\$ (7,329)	\$ (12,331)	\$ (27,176)	\$ (29,346)
LOSS PER SHARE - BASIC AND DILUTED	\$ (0.04)	\$ (0.06)	\$ (0.14)	\$ (0.15)
Weighted average shares outstanding - basic and diluted	198,197,366	195,196,597	198,180,409	195,196,597

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

JUSHI HOLDINGS INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)
(in thousands of U.S. dollars, except share amounts)

	Six Months Ended June 30, 2026					
	Subordinate Voting Shares	Paid-In Capital	Accumulated Deficit	Total Jushi Shareholders' Equity (Deficit)	Non- Controlling Interests	Total Equity (Deficit)
Balances - January 1, 2026	199,696,597	\$ 511,868	\$ (627,212)	\$ (115,344)	\$ —	\$ (115,344)
Share-based compensation (including related parties)	—	392	—	392	—	392
Net loss	—	—	(19,847)	(19,847)	—	(19,847)
Balances - March 31, 2026	199,696,597	\$ 512,260	\$ (647,059)	\$ (134,799)	\$ —	\$ (134,799)
Share-based compensation (including related parties)	—	312	—	312	—	312
Shares issued upon exercise of stock options	1,666	—	—	—	—	—
Net loss	—	—	(7,329)	(7,329)	—	(7,329)
Balances - June 30, 2026	199,698,263	\$ 512,572	\$ (654,388)	\$ (141,816)	\$ —	\$ (141,816)

	Six Months Ended June 30, 2025					
	Subordinate Voting Shares	Paid-In Capital	Accumulated Deficit	Total Jushi Shareholders' Equity (Deficit)	Non- Controlling Interests	Total Equity (Deficit)
Balances - January 1, 2025	196,696,597	\$ 508,386	\$ (558,621)	\$ (50,235)	\$ —	\$ (50,235)
Share-based compensation (including related parties)	—	(307)	—	(307)	—	(307)
Reclassification of warrants	—	1,377	—	1,377	—	1,377
Recognition of non-controlling interest in acquisition	—	—	—	—	300	300
Net loss	—	—	(17,015)	(17,015)	—	(17,015)
Balances - March 31, 2025	196,696,597	\$ 509,456	\$ (575,636)	\$ (66,180)	\$ 300	\$ (65,880)
Share-based compensation (including related parties)	—	374	—	374	—	374
Net loss	—	—	(12,331)	(12,331)	—	(12,331)
Balances - June 30, 2025	196,696,597	\$ 509,830	\$ (587,967)	\$ (78,137)	\$ 300	\$ (77,837)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

JUSHI HOLDINGS INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands of U.S. dollars)

	Six Months Ended June 30,	
	2026	2025
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	\$ (27,176)	\$ (29,346)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation and amortization, including amounts in cost of goods sold	17,178	16,002
Share-based compensation	704	67
Fair value changes in derivatives	(2,645)	(450)
Non-cash interest expense, including amortization of deferred financing costs	3,733	4,632
Deferred income taxes and uncertain tax positions	6,812	17,583
Loss on debt extinguishment/modification	5,016	—
Asset impairment	1,334	—
Loss (gain) on asset disposals	68	(3,009)
Other non-cash items, net ⁽¹⁾	3,450	(531)
Changes in operating assets and liabilities:		
Accounts receivable	60	942
Inventory	(447)	2,086
Prepaid expenses and other current and non-current assets	838	384
Accounts payable, accrued expenses and other current liabilities	480	(2,766)
Net cash flows provided by operating activities	9,405	5,594
CASH FLOWS FROM INVESTING ACTIVITIES:		
Payments for property, plant and equipment	(6,928)	(8,137)
Investments in intangible assets	(1,610)	(647)
Proceeds from sale of assets	561	3,950
Net cash flows used in investing activities	(7,977)	(4,834)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from Debt, net	17,483	4,608
Proceeds from other financing activities	—	750
Debt principal paid	(7,298)	(297)
Payments of finance leases	(1,154)	(925)
Payments of loan financing costs	(605)	—
Payments of other financing activities	(1,016)	(1,011)
Net cash flows provided by financing activities	7,410	3,125
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	8,838	3,885
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD	26,616	21,346
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD	\$ 35,454	\$ 25,231

⁽¹⁾ For the six months ended June 30, 2026, Other non-cash items, net includes \$3,305 accrued interest settled by a third-party lender.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

JUSHI HOLDINGS INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
(In thousands of U.S. dollars)

	Six Months Ended June 30,	
	2026	2025
SUPPLEMENTAL CASH FLOW INFORMATION:		
Cash paid for interest (excluding capitalized interest)	\$ 12,277	\$ 15,171
Cash paid for income taxes	\$ 1,088	\$ 1,403
NON-CASH INVESTING AND FINANCING ACTIVITIES:		
Capital expenditures	\$ 1,825	\$ 2,648
Right-of-use assets from finance lease liabilities	\$ 307	\$ 1,738
Issuance of promissory notes for acquisitions	\$ 1,355	\$ 5,909
Warrants issued for Second Lien Notes	\$ —	\$ 1,769
Financed insurance premiums	\$ 516	\$ —
Property, plant and equipment from finance lease liabilities	\$ 215	\$ 628
2026 Term Loan used to settle Second Lien Notes and 2024 Term Loan, and refinancing fees	\$ 136,117	\$ —
Debt Original Issue Discount	\$ 6,400	\$ 512

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

JUSHI HOLDINGS INC.**Notes to the Unaudited Condensed Consolidated Financial Statements***(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)*

1. NATURE OF OPERATIONS

Jushi Holdings Inc. (the “Company” or “Jushi”) is incorporated under British Columbia’s Business Corporations Act. The Company is a vertically integrated, multi-state cannabis operator engaged in retail, distribution, cultivation, and processing in both medical and adult-use markets. As of June 30, 2026, Jushi, through its subsidiaries, owns or manages cannabis operations and/or holds licenses in the adult-use and/or medicinal cannabis marketplace in California, Illinois, Massachusetts, Nevada, New Jersey, Ohio, Pennsylvania and Virginia. The Company’s head office is located at 301 Yamato Road, Suite 3250, Boca Raton, Florida 33431, United States of America, and its registered address is Suite 1700, Park Place, 666 Burrard Street, Vancouver, British Columbia V6C 2X8, Canada.

The Company is listed on the Canadian Securities Exchange (“CSE”) and trades its subordinate voting shares (“SVS”) under the ticker symbol “JUSH”. The Company’s SVS trade in the United States on the OTCQX® Best Market (“OTCQX”) under the symbol “JUSHF”.

Proposed Continuance from British Columbia to Nevada

On June 24, 2026, the Company held its annual general and special meeting of the shareholders during which the shareholders voted in favor of a proposed arrangement (the “Arrangement”) which involves, among other things, the continuance of the Company out from the province of British Columbia, Canada and the concurrent domestication of the Company in the State of Nevada in the United States. The Arrangement, if effectuated, is not expected to cause any material change to the Company’s business or operations.

2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Consolidation

The financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and footnotes. Actual results could differ materially from those estimates.

In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments, of a normal recurring nature, that are necessary to present fairly the financial position, results of operations and cash flows of the Company for the periods, and at the dates, presented. The results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2025, which are included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 31, 2026 (the “2025 Form 10-K”), and also filed on the System for Electronic Document Analysis and Retrieval (“SEDAR”) on March 31, 2026. Consolidated balance sheet information as of December 31, 2025 presented herein is derived from the Company’s audited consolidated financial statements for the year ended December 31, 2025.

JUSHI HOLDINGS INC.**Notes to the Unaudited Condensed Consolidated Financial Statements***(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)***Summary of Significant Accounting Policies**

The Company's significant accounting policies are described in Note 2 in the audited consolidated financial statements and notes thereto for the year ended December 31, 2025, which is included in the 2025 Form 10-K. There have been no material changes to the Company's significant accounting policies.

Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows:

	June 30, 2026 (unaudited)	December 31, 2025
Cash and cash equivalents	\$ 33,329	\$ 24,047
Restricted cash included in Prepaid expenses and other current assets	—	444
Restricted cash - non-current	2,125	2,125
Cash, cash equivalents and restricted cash	<u>\$ 35,454</u>	<u>\$ 26,616</u>

Recent Accounting Pronouncements*Adoption of New Accounting Standards*

In July 2025, the FASB issued ASU 2025-05, *Measurement of Credit Losses for Accounts Receivable and Contract Assets*, which provide entities with a practical and expedient approach to simplify the estimation of expected credit losses on current accounts receivable and current contract assets that arise from transactions accounted for under Accounting Standards Codification ("ASC") 606, *Revenue from Contracts with Customers*, by allowing the assumption that current conditions as of the balance sheet date will not change during the remaining life of the asset. ASU 2025-05 is effective for annual periods beginning after December 15, 2025 and interim periods within those annual reporting periods, with early adoption permitted. The adoption of this pronouncement did not have any impact on the Company's consolidated financial statements and related disclosures.

Accounting Standards Issued But Not Yet Adopted

In November 2024, the FASB issued ASU 2024-03, *Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses*, which requires an entity to improve disclosures about public business entities' expenses and to provide more detailed information around the types of expenses included in commonly presented expense captions. Additionally, in January 2025 the FASB issued ASU 2025-01 to clarify the effective date of ASU 2024-03. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods for fiscal years beginning after December 15, 2027, and can be applied on a prospective basis or on a retrospective basis to all periods presented. Early adoption is permitted. The Company is currently evaluating the effect of these pronouncements on its consolidated financial statements and related disclosures.

In May 2025, the FASB issued ASU 2025-03, *Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity*, which clarifies that when a business that is a VIE is acquired primarily with equity interests, the determination of the accounting acquirer should follow ASC 805 rather than defaulting to the primary beneficiary under ASC 810. ASU 2025-03 is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the effect of this pronouncement on its consolidated financial statements and related disclosures.

In December 2025, the FASB issued ASU 2025-11, *Interim Reporting (Topic 270): Narrow-Scope Improvements*, which amends the guidance in Topic 270, Interim Reporting. ASU 2025-11 improves the navigability of the required interim disclosures and clarifies when that guidance is applicable. ASU 2025-11 also provides additional guidance on what disclosures should be provided in interim reporting periods and adds a principle that requires entities to disclose events

JUSHI HOLDINGS INC.**Notes to the Unaudited Condensed Consolidated Financial Statements***(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)*

since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 does not change the fundamental nature of interim reporting or expand or reduce current interim disclosure requirements, and is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the effect of this pronouncement on its consolidated financial statements and related disclosures.

3. INVENTORIES, NET

The components of inventories, net, are as follows:

	June 30, 2026 (unaudited)	December 31, 2025
Raw materials	\$ 10,522	\$ 10,312
Work in process	6,249	6,855
Finished goods	17,528	17,440
Total inventories, net	<u>\$ 34,299</u>	<u>\$ 34,607</u>

4. PREPAID EXPENSES AND OTHER CURRENT ASSETS

The components of prepaid expenses and other current assets are as follows:

	June 30, 2026 (unaudited)	December 31, 2025
Prepaid expenses and deposits	\$ 3,428	\$ 3,676
Employee retention credit receivable	688	688
Assets held for sale	—	382
Other current assets	1,238	2,112
Total prepaid expenses and other current assets	<u>\$ 5,354</u>	<u>\$ 6,858</u>

5. PROPERTY, PLANT AND EQUIPMENT

The components of property, plant and equipment (“PPE”) are as follows:

	June 30, 2026 (unaudited)	December 31, 2025
Buildings and building components	\$ 90,179	\$ 91,225
Land	11,698	12,956
Leasehold improvements	60,790	55,775
Machinery and equipment	25,612	24,946
Furniture, fixtures and office equipment	24,629	23,769
Construction-in-process	3,880	4,808
Total property, plant and equipment - gross	<u>216,788</u>	<u>213,479</u>
Less: Accumulated depreciation	<u>(79,611)</u>	<u>(70,158)</u>
Total property, plant and equipment - net	<u>\$ 137,177</u>	<u>\$ 143,321</u>

Construction-in-process represents assets under construction for manufacturing and retail build-outs not yet ready for use.

JUSHI HOLDINGS INC.**Notes to the Unaudited Condensed Consolidated Financial Statements***(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)*

Depreciation was \$5,097 and \$4,435 for the three months ended June 30, 2026 and 2025, respectively, and \$9,107 and \$8,937 for the six months ended June 30, 2026 and 2025, respectively. Interest expense capitalized to PPE totaled \$153 and \$43 for the three months ended June 30, 2026 and 2025, respectively, and \$246 and \$105 for the six months ended June 30, 2026 and 2025, respectively.

Long-lived Asset Impairment

During the three months ended June 30, 2026, the Company determined that indicators of impairment existed at certain dispensaries pending relocation. As a result, the Company recorded a non-cash impairment charge of \$1,334 related to long-lived assets associated with these dispensaries, which is included in operating expenses in the condensed consolidated statements of operations. The impairment charge was determined based on estimated fair values using Level 3 inputs, including cash flows over the remaining asset lives.

6. OTHER NON-CURRENT ASSETS

The components of other non-current assets are as follows:

	June 30, 2026 (unaudited)	December 31, 2025
Operating lease assets	\$ 21,087	\$ 19,724
Net deferred tax assets	12,719	5,145
Deposits and escrows - properties	1,721	1,699
Indemnification assets	521	499
Deposits - equipment	336	386
Other	395	348
Total other non-current assets	<u>\$ 36,779</u>	<u>\$ 27,801</u>

7. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

The components of accrued expenses and other current liabilities are as follows:

	June 30, 2026 (unaudited)	December 31, 2025
Accrued employee related expenses and liabilities	\$ 6,099	\$ 5,955
Operating lease obligations	6,214	6,035
Goods received not invoiced	2,048	2,961
Accrued interest	2,676	1,945
Accrued sales and excise taxes	1,915	1,749
Deferred revenue (loyalty program)	1,443	1,596
Accrued professional and management fees	594	564
Deferred income - employee retention credit	688	688
Accrued capital expenditures	847	210
Other accrued expenses and current liabilities	3,381	3,828
Total accrued expenses and other current liabilities	<u>\$ 25,905</u>	<u>\$ 25,531</u>

JUSHI HOLDINGS INC.
Notes to the Unaudited Condensed Consolidated Financial Statements
(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)

8. DEBT

The components of the Company's debt are as follows:

	Effective Interest Rate	Maturity Date	June 30, 2026 (unaudited)	December 31, 2025
Principal amounts:				
2026 Term Loan	16%	March 2029	\$ 160,000	\$ —
Second Lien Notes	n/a	n/a	—	86,194
2024 Term Loan	n/a	n/a	—	46,075
Acquisition-related promissory notes payable	8% - 12%	August 2026 - April 2027	27,576	28,337
Mortgage loans	6% - 10%	January 2027 - September 2030	32,222	32,470
Total debt subject to scheduled repayments			219,798	193,076
Promissory notes payable to Sammartino ⁽¹⁾	10%	September 2024 - September 2026	21,500	21,500
Total debt			241,298	214,576
Less: debt issuance costs and original issue discounts			(11,299)	(8,742)
Total debt, net			\$ 229,999	\$ 205,834
Debt, net - current portion			\$ 33,623	\$ 6,639
Debt, net - non-current portion			\$ 196,376	\$ 199,195

⁽¹⁾ This amount is related to the promissory notes issued to Sammartino Investments LLC ("Sammartino") in connection with the acquisition of Nature's Remedy of Massachusetts, Inc. ("Nature's Remedy") in September 2021. The Company currently has no obligation to pay the principal and interest. See further discussion of the Sammartino Matter in Note 16 - Commitments and Contingencies for more information.

2026 Term Loan

On March 27, 2026, the Company refinanced both its senior secured term loan ("2024 Term Loan") and its 12% second lien notes due 2026 ("Second Lien Notes"), which had outstanding principal balances of \$46,075 and \$86,194, respectively, as of December 31, 2025, and were scheduled to mature within twelve months of December 31, 2025. The refinancing of the 2024 Term Loan and Second Lien Notes was accounted for as a partial extinguishment resulting in a loss on debt extinguishment/modification of \$5,016, which is included in other income (expense), net in the consolidated statements of operations. The refinancing was completed through the issuance of a \$160,000 senior secured term loan ("2026 Term Loan") to a syndicate of lenders, bearing interest at a rate of 12.5% per annum payable in cash monthly with maturity in March 2029, and an original issue discount of \$6,400. The 2026 Term Loan lender used \$136,117 to: (i) settle the outstanding principal, accrued but unpaid interest, exit fee and make-whole on the 2024 Term Loan; (ii) settle the outstanding principal and accrued but unpaid interest on the Second Lien Notes; and (iii) pay certain fees and expenses associated with the issuance of the 2026 Term Loan. Remaining excess proceeds of \$17,483 were retained on the balance sheet for general corporate purposes.

Serpentine Capital Management III, LLC, an entity controlled by James Cacioppo, the Company's Chief Executive Officer, Chairman and founder, participated in the 2026 Term Loan with a principal amount of \$27,993. Denis Arsenault, a founder and significant equity holder of the Company, participated in the 2026 Term Loan with a principal amount of \$21,016.

JUSHI HOLDINGS INC.**Notes to the Unaudited Condensed Consolidated Financial Statements***(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)***Acquisition-related promissory notes payable**Statewide

In February 2025, in connection with an Asset Purchase Agreement with Statewide Property Holdings Ohio, LLC (“Statewide”), the Company issued a promissory note in the principal amount of \$2,161 with a stated interest rate of 9% per annum and maturity date in June 2026. The promissory note provided for full principal and interest payments on the maturity date. The promissory note, together with accrued but unpaid interest, was paid in full in June 2026.

RJK

In February 2025, in connection with an Asset Purchase Agreement with RJK Holdings of Ohio, LLC (“RJK”), the Company issued a promissory note in the principal amount of \$4,063 with a stated interest rate of 9% per annum and which matures in August 2026.

Parma

In the first half of 2025, the Company entered into agreements to acquire a dispensary license and assume an existing lease in Parma, Ohio, subject to regulatory approval, for a total purchase price of \$3,200. The Company paid an initial deposit of \$250. In February 2026, the transaction closed upon receipt of regulatory approval, and the remaining consideration was paid through a combination of \$1,550 in cash and \$1,400 in aggregate promissory notes. The promissory notes bear interest at a stated rate of 10% per annum, are payable quarterly in cash, and mature in April 2027.

The transaction was accounted for as an asset acquisition, as the acquired set did not constitute a business due to the absence of a transferred workforce, customers, substantive processes, or revenue-generating activities. Accordingly, the acquisition was accounted for under ASC 805-50, and no goodwill was recognized. The right-of-use asset recognized for the assumed lease approximated the corresponding lease liability and therefore did not require allocation of the consideration transferred. As a result, substantially all of the consideration was allocated to the acquired dispensary license, which is recorded as a finite-lived intangible asset and is being amortized on a straight-line basis over an estimated useful life of 15 years.

Mortgage LoansArlington Mortgage

In December 2021, the Company entered into a \$6,900 mortgage loan agreement (the “Arlington Mortgage”), which is principally secured by the Company’s retail property in Arlington, Virginia. The Arlington Mortgage bears a fixed interest rate of 5.875% per annum, payable monthly, and will mature in January 2027.

Dickson City Mortgage

In July 2022, the Company entered into a \$2,800 mortgage loan agreement (the “Dickson City Mortgage”), which is principally secured by the Company’s retail property in Dickson City, Pennsylvania. The Dickson City Mortgage matures in July 2027 and bears interest at a variable rate equal to prime rate plus 2%. The interest rate as of June 30, 2026 was 8.75%.

Manassas Mortgage

In April 2023, the Company entered into a \$20,000 mortgage loan agreement (the “Manassas Mortgage”), which is principally secured by the Company’s cultivation and manufacturing facility located in Manassas, Virginia (the “Property”). The Manassas Mortgage requires monthly payments and was originally scheduled to mature in April 2028. The interest rate is variable and determined based on the 30-day average secured overnight financing rate plus 3.55%.

JUSHI HOLDINGS INC.**Notes to the Unaudited Condensed Consolidated Financial Statements***(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)*

In September 2025, the Company executed a modification agreement (the “Modification Agreement”) related to the Manassas Mortgage, pursuant to which: (i) the outstanding principal balance was increased by \$4,000, (the “Additional Loan Proceeds”); (ii) the loan’s maturity date was extended to September 2030; and (iii) the interest rate floor was lowered from 8.25% to 7.50% (the interest rate remains the average 30-day secured overnight financing rate plus 3.55%). The Manassas Mortgage, as modified, remains principally secured by the Property. In addition, as part of the Modification Agreement, the Company was required to deposit \$761 of the Additional Loan Proceeds into a restricted account, designated for use in fulfilling certain conditions associated with ongoing construction at the Property.

The interest rate as of June 30, 2026 was 7.50%.

Financial Covenants2026 Term Loan

The 2026 Term Loan includes a financial covenant that requires the Company to maintain a minimum unrestricted cash balance of \$15,000 at all times. As of June 30, 2026, the Company was in compliance with this financial covenant.

Mortgage loans

The Company’s three mortgage loan agreements contain certain financial and other covenants with which the Company is required to comply. As of June 30, 2026, the Company was in compliance with all financial covenants contained in each of the mortgage loan agreements.

Annual Maturities

As of June 30, 2026, aggregate future scheduled repayments of the Company’s debt were as follows:

	Remainder of the year	2027	2028	2029	2030	Total
2026 Term Loan	\$ —	\$ —	\$ —	\$ 160,000	\$ —	\$ 160,000
Acquisition-related promissory notes payable	4,062	23,514	—	—	—	27,576
Mortgage loans	257	9,308	383	418	21,856	32,222
Total debt subject to scheduled repayments	\$ 4,319	\$ 32,822	\$ 383	\$ 160,418	\$ 21,856	\$ 219,798

The above table excludes the maturities of the Company’s promissory notes payable to Sammartino, as the repayment of these notes, if any, would arise in the context of a non-appealable final judgment by a court. Refer to Note 16 - Commitments and Contingencies for more information. Specifically, the promissory notes that were payable to Sammartino are as follows: \$16,500 in 2024 and \$5,000 in 2026. However, these balances are classified as long-term debt since the Company does not expect to repay these amounts within the next 12 months.

JUSHI HOLDINGS INC.
Notes to the Unaudited Condensed Consolidated Financial Statements
(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)

Interest Expense

Interest expense, net is comprised of the following:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Interest expense				
Interest and accretion - Second Lien Notes	\$ —	\$ 3,390	\$ 3,382	\$ 6,493
Interest and accretion - 2024 Term Loan	—	2,930	2,814	6,120
Interest and accretion - 2026 Term Loan	6,127	—	6,401	—
Interest and accretion - Finance lease liabilities	2,555	2,523	5,104	4,998
Interest and accretion - Promissory notes	942	921	1,873	1,735
Interest and accretion - Mortgage loans and other financing activities	624	605	1,243	1,207
Capitalized interest	(153)	(43)	(246)	(105)
Total interest expense	10,095	10,326	20,571	20,448
Interest income	(209)	(107)	(297)	(229)
Total interest expense, net	<u>\$ 9,886</u>	<u>\$ 10,219</u>	<u>\$ 20,274</u>	<u>\$ 20,219</u>

9. DERIVATIVE LIABILITIES

The following table summarizes the change in the Company's derivative liabilities for the six months ended June 30, 2026.

	Total Derivative Liabilities ⁽¹⁾
Balance as of January 1, 2026	\$ 8,607
Fair value changes	(2,645)
Balance as of June 30, 2026	<u>\$ 5,962</u>

⁽¹⁾ Refer to Note 10 - Equity for the change in number of warrants during the six months ended June 30, 2026.

The Company's derivative liabilities are primarily comprised of derivative warrants ("Derivative Warrants"). These are warrants to purchase SVS of the Company and were issued in connection with the Company's Second Lien Notes and the 2024 Term Loan. The Derivative Warrants may be net share settled.

As of June 30, 2026 and December 31, 2025 there were 21,400,000 Derivative Warrants outstanding, which consisted of (i) 2,000,000 warrants with an exercise price of \$2.086 per warrant and an expiration date in December 2026, and (ii) 19,400,000 warrants with an exercise price of \$1.00 per warrant and an expiration date in July 2029.

Derivative Warrants are considered derivative financial liabilities measured at fair value with all gains or losses recognized in profit or loss as the settlement amount for the Derivative Warrants may be adjusted during certain periods for variables that are not inputs to standard pricing models for forward or option equity contracts, i.e., the "fixed for fixed" criteria under ASC 815-40. The estimated fair value of the Derivative Warrants is measured at the end of each reporting period and an adjustment is reflected in fair value changes in derivatives in the consolidated statements of operations. These are Level 3 recurring fair value measurements. The estimated fair value of the Derivative Warrants was determined using the Black-Scholes model with stock price based on the OTCQX closing price of the Derivative Warrants as of June 30, 2026 and December 31, 2025.

JUSHI HOLDINGS INC.
Notes to the Unaudited Condensed Consolidated Financial Statements
(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)


The assumptions used in the fair value calculations as of the balance sheet dates presented include the following:

	June 30, 2026 (unaudited)	December 31, 2025
Stock price per share	\$0.49	\$0.63
Risk-free annual interest rate	3.97% - 4.15%	3.48% - 3.60%
Range of estimated possible exercise price	\$1.00 - \$2.086	\$1.00 - \$2.086
Weighted average volatility	119%	118%
Remaining life	0.4 - 3.1 years	0.9 - 3.6 years
Forfeiture rate	0%	0%
Expected annual dividend yield	0%	0%

Volatility was estimated by using a weighting of the Company's historical volatility. The risk-free interest rate for the expected life of the Derivative Warrants was based on the yield available on government benchmark bonds with an approximate equivalent remaining term. The expected life is based on the contractual term. If any of the assumptions used in the calculation were to increase or decrease, this could result in a material or significant increase or decrease in the estimated fair value of the derivative liability. For example, the following table illustrates an increase or decrease in certain significant assumptions as of the balance sheet dates:

	As of June 30, 2026 (unaudited)			As of December 31, 2025		
	Input	Effect of 10% Increase	Effect of 10% Decrease	Input	Effect of 10% Increase	Effect of 10% Decrease
Stock price per share	\$ 0.49	\$ 763	\$ (748)	\$ 0.63	\$ 1,075	\$ (1,057)
Volatility	119 %	571	(631)	118 %	713	(792)

10. EQUITY

Authorized, Issued and Outstanding

The authorized share capital of the Company consists of an unlimited number of SVS, Multiple Voting Shares, Super Voting Shares, and Preferred Shares. As of June 30, 2026, the Company had 199,698,263 SVS issued and outstanding and no Multiple Voting Shares, Super Voting Shares or Preferred Shares issued and outstanding.

JUSHI HOLDINGS INC.**Notes to the Unaudited Condensed Consolidated Financial Statements***(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)***Warrants**

Each warrant entitles the holder to purchase one SVS. Certain warrants may be net share settled. The following table summarizes the status of warrants and related transactions:

	Non-Derivative (Equity) Warrants	Derivative Liabilities Warrants	Total Number of Warrants	Weighted - Average Exercise Price
Balance as of January 1, 2026	57,994,087	21,400,000	79,394,087	\$ 0.95
Granted	100,000	—	100,000	\$ 0.48
Balance as of June 30, 2026	58,094,087	21,400,000	79,494,087	\$ 0.95
Exercisable as of June 30, 2026	56,724,087	21,400,000	78,124,087	\$ 0.96

The grant date fair value of the non-derivative warrants issued was determined using the Black-Scholes option-pricing model. The following assumptions were used for the calculation at date of issuance:

Weighted average stock price	\$0.49
Weighted average expected stock price volatility	106.4%
Expected annual dividend yield	0%
Weighted average expected life of warrants	5.0 years
Weighted average risk-free annual interest rate	4.2%
Weighted average grant date fair value	\$0.39

Share-based Payment Award Plans***Plan summary and description***

Under the Company's 2019 Equity Incentive Plan, as amended, (the "2019 Plan"), non-transferable options to purchase SVS and restricted SVS of the Company may be issued to directors, officers, employees, or consultants of the Company. The 2019 Plan authorizes the issuance of up to 15% (plus an additional 2% inducements for hiring employees and senior management) of the number of outstanding shares of common stock (of all classes) of the Company (the "Share Reserve"). Incentive stock options are limited to the Share Reserve, and the maximum number of incentive awards available for issuance under the 2019 Plan, including additional awards available for certain new hires, was 7,030,785 as of June 30, 2026.

Stock Options

The stock options issued by the Company are options to purchase SVS of the Company. All stock options issued have been issued to directors and employees under the Company's 2019 Plan. Such options generally expire ten years from the date of grant and generally vest ratably over three years from the grant date. The options generally may be net share settled.

JUSHI HOLDINGS INC.
Notes to the Unaudited Condensed Consolidated Financial Statements
(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)


The following table summarizes the status of stock options and related transactions:

	Number of Stock Options	Weighted-Average Per Share Exercise Price
Issued and Outstanding as of January 1, 2026	26,597,918	\$ 0.75
Granted	420,000	\$ 0.48
Exercised	(1,666)	\$ 0.30
Cancelled/forfeited/expired	(98,333)	\$ 0.59
Issued and Outstanding as of June 30, 2026	26,917,919	\$ 0.74
Exercisable as of June 30, 2026	20,050,888	\$ 0.82

The fair value of the stock options granted was determined using the Black-Scholes option-pricing model. The following assumptions were used for the calculation at date of grant:

	Six Months Ended June 30,	
	2026	2025
Weighted average stock price	\$0.47	\$0.29
Weighted average expected stock price volatility	104.3%	92.0%
Expected annual dividend yield	0%	0%
Weighted average expected life	5.4 years	5.0 years
Weighted average risk-free annual interest rate	4.3%	4.0%
Weighted average grant date fair value	\$0.38	\$0.21

Restricted Shares

During the six months ended June 30, 2026, 3,000,000 restricted SVS vested and were released. There was no unvested restricted SVS as of June 30, 2026.

Share-based Compensation Cost

The components of share-based compensation expense, net, are as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Stock options expense (forfeiture)	\$ 255	\$ 307	\$ 520	\$ (74)
Restricted stock	—	—	68	—
Warrants	57	67	116	141
Total share-based compensation expense, net	\$ 312	\$ 374	\$ 704	\$ 67

As of June 30, 2026, the Company had \$1,259 of unrecognized share-based compensation cost related to unvested stock options and warrants, which is expected to be recognized as share-based compensation cost over a weighted average period of 1.7 years.

JUSHI HOLDINGS INC.
Notes to the Unaudited Condensed Consolidated Financial Statements
(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)

11. LOSS PER SHARE

The reconciliations of the net loss and the weighted average number of shares used in the computations of basic and diluted loss per share are as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Numerator:				
Net loss	\$ (7,329)	\$ (12,331)	\$ (27,176)	\$ (29,346)
Denominator:				
Weighted-average shares of common stock - basic and diluted	198,197,366	195,196,597	198,180,409	195,196,597
Loss per common share:				
Basic and diluted	\$ (0.04)	\$ (0.06)	\$ (0.14)	\$ (0.15)

The following table summarizes weighted average instruments that may, in the future, have a dilutive effect on earnings (loss) per share, but were excluded from consideration in the computation of diluted net loss per share for the three and six months ended June 30, 2026 and 2025, because the impact of including them would have been anti-dilutive:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Stock options	26,734,036	24,545,305	26,653,407	25,108,643
Warrants (derivative liabilities and equity)	79,410,571	79,929,162	79,402,374	77,494,994
	106,144,607	104,474,467	106,055,781	102,603,637

12. REVENUE

The Company has two revenue streams: (i) retail and (ii) wholesale. The Company's retail revenue is comprised of cannabis sales from its dispensaries. The Company's wholesale revenue is comprised of cannabis sales to its wholesale customers for resale through their dispensaries. Any intercompany revenue and costs are eliminated to arrive at consolidated totals.

The following table summarizes the Company's revenue from external customers, disaggregated by revenue stream:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Retail	\$ 61,867	\$ 59,440	\$ 119,741	\$ 116,284
Wholesale	9,430	5,606	17,988	12,608
Total revenue, net	\$ 71,297	\$ 65,046	\$ 137,729	\$ 128,892

JUSHI HOLDINGS INC.
Notes to the Unaudited Condensed Consolidated Financial Statements
(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)

13. OPERATING EXPENSES

The major components of operating expenses are as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Salaries, wages and employee related expenses	\$ 14,890	\$ 14,591	\$ 29,610	\$ 28,740
Depreciation and amortization expenses	4,726	4,593	8,424	9,190
Rent and related expenses	2,946	3,034	6,168	6,231
Professional fees and legal expenses	1,880	1,855	4,218	3,780
Long-lived asset impairment	1,334	—	1,334	—
Software and technology expenses	1,141	1,102	2,384	2,175
Share-based compensation expense	312	374	704	67
Loss (gain) on asset disposals and lease terminations	168	(3,424)	57	(3,298)
Other expenses ⁽¹⁾	3,419	3,197	6,211	6,083
Total operating expenses	<u>\$ 30,816</u>	<u>\$ 25,322</u>	<u>\$ 59,110</u>	<u>\$ 52,968</u>

⁽¹⁾ Other expenses are primarily comprised of marketing and selling expenses, insurance costs, administrative and licensing fees, travel, entertainment and other.

14. INCOME TAXES

The following table summarizes the Company's income tax expense and effective tax rates for the three and six months ended June 30, 2026 and 2025:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Loss before income tax	\$ (8,305)	\$ (2,403)	\$ (19,435)	\$ (10,440)
Income tax benefit (expense)	\$ 976	\$ (9,928)	\$ (7,741)	\$ (18,906)
Effective income tax rate	11.8 %	(413.2)%	(39.8)%	(181.1)%

The Company computed its provision for income taxes for the three and six months ended June 30, 2026 using the actual effective tax rate for each respective interim period, taking into consideration the impact of the U.S. Department of Justice's regulatory action, effective April 28, 2026, reclassifying certain state-licensed medical marijuana products and FDA-approved marijuana products from Schedule I to Schedule III under the Controlled Substances Act (the "Rescheduling Rule"). The Company computed its provision for income taxes for the three and six months ended June 30, 2025 using the actual effective tax rate for each respective interim period. Therefore, the Company's effective income tax rates for the three and six months ended June 30, 2026 and 2025 are not indicative of the effective income tax rate for each respective fiscal year of 2026 and 2025. The Company's effective income tax rate differs significantly from the applicable statutory income tax rates due in part to (i) uncertain tax position liabilities associated with tax positions under Internal Revenue Code Section 280E ("280E") relating to adult-use cannabis activities, qualifying medical cannabis activities occurring before April 28, 2026, and prior taxable years, (ii) interest and penalties associated with uncertain tax positions, and (iii) state income taxes. These items were partially offset during the three and six months ended June 30, 2026 by a net discrete income tax benefit of approximately \$6,397 resulting from the reassessment of unrecognized tax benefits associated with certain deferred tax balances following the federal rescheduling of qualifying medical cannabis activities, as described below.

JUSHI HOLDINGS INC.**Notes to the Unaudited Condensed Consolidated Financial Statements***(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)*

The Internal Revenue Service (“IRS”) has historically taken the position that cannabis companies are subject to the limitation of 280E, a position held by state tax regulators in Nevada, Ohio and Virginia. Under the IRS’s interpretation of 280E, cannabis companies are only allowed to deduct expenses directly and indirectly related to the production of inventory. The Rescheduling Rule states that qualifying medical cannabis activities conducted by state-licensed entities will no longer be subject to the deduction disallowance imposed by 280E. The Rescheduling Rule also established an expedited process for state-licensed medical cannabis entities, including medical marijuana dispensaries, to register with the U.S. Drug Enforcement Administration (“DEA”), enabling qualifying registrants to engage in the manufacture, distribution and/or dispensing of cannabis for medical purposes under federal law. The Company has submitted DEA registration applications for its medical and dual-use operations, and all such applications remain pending as of the date of this Quarterly Report on Form 10-Q (this “report”). The Rescheduling Rule further provides that the U.S. Department of Treasury and the IRS will be issuing formal guidance addressing the federal income tax implications of the Rescheduling Rule, including transition and allocation matters. As of the date of this report, the U.S. Department of Treasury and IRS have not issued any formal guidance. Consequently, in preparing its income tax provision for the three and six months ended June 30, 2026, the Company applied its interpretation of the effects of the Rescheduling Rule beginning on its April 28, 2026 effective date. The Company will reassess its conclusions and methodology upon the issuance of formal guidance or other relevant legal or regulatory developments.

Based on the Rescheduling Rule and the facts and circumstances existing as of June 30, 2026, management concluded that, beginning April 28, 2026, 280E does not limit deductions and credits attributable to the Company's qualifying state-licensed medical cannabis activities and that the related tax benefits meet the more-likely-than-not recognition threshold under ASC 740, *Income Taxes*. Accordingly, the Company did not record an uncertain tax position for deductions and credits attributable to qualifying state-licensed medical cannabis activities occurring on or after April 28, 2026. The Company continued to record uncertain tax positions for deductions attributable to adult-use cannabis activities, qualifying medical cannabis activities occurring before April 28, 2026, and tax positions relating to prior taxable years.

In connection with the preparation and filing of the fiscal 2022 income tax return, the Company changed its previous application of 280E to exclude certain parts of its business. In regards to fiscal years 2023 through 2026, the Company has taken the position that its deductions of ordinary and necessary business expenses are not limited by 280E. However, since the Company’s tax positions on 280E may be challenged by taxing authorities, the Company elected to treat the deductibility of these related expenses as an uncertain tax position except for the tax benefits attributable to qualifying state-licensed medical cannabis activities occurring on or after April 28, 2026 that were recognized based on the Rescheduling Rule. As of June 30, 2026 and December 31, 2025, the balances in income tax payable and unrecognized tax benefits on the consolidated balance sheets include the impact of the tax position on 280E, which decreased current liabilities with a corresponding increase in non-current liabilities. There was no material impact to the consolidated statement of operations.

During the three months ended June 30, 2026, the Company reassessed the unrecognized tax benefits associated with deferred tax balances existing as of January 1, 2026. The Company concluded that certain unrecognized tax benefits attributable to qualifying state-licensed medical cannabis activities should be reduced because the underlying temporary differences are expected to reverse on or after April 28, 2026, when 280E is no longer expected to limit the related deductions and credits. As a result of this reassessment, the Company recognized a net discrete income tax benefit of \$6,397 during the three months ended June 30, 2026. The reassessment did not reflect retroactive application of the Rescheduling Rule to qualifying state-licensed medical cannabis activities occurring before April 28, 2026.

In February 2026, the IRS issued a Notice of Proposed Adjustment (“NOPA”) in connection with its audit of the Company's tax year ended December 31, 2021. The Company submitted a response to the NOPA disputing the proposed adjustments. The response reflects substantive and procedural arguments that Jushi believes have merit, and the Company plans to defend its position vigorously. The proposed tax amounts were previously included in the Company's liability for unrecognized tax benefits.

JUSHI HOLDINGS INC.
Notes to the Unaudited Condensed Consolidated Financial Statements
(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)


The Company has a liability for unrecognized tax benefits of \$193,946 and \$177,242 as of June 30, 2026 and December 31, 2025, respectively, inclusive of interest and penalties of \$45,233 and \$38,342, respectively. The Company anticipates that it is reasonably possible that its new tax position on 280E may require changes to the balance of unrecognized tax benefits within the next 12 months. However, an estimate of such changes cannot reasonably be made.

The total amount of interest and penalties related to the liability for unrecognized tax benefits recorded in income tax expense during the three months ended June 30, 2026 and 2025 was \$3,708 and \$2,987, respectively. The total amount of interest and penalties related to the liability for unrecognized tax benefits recorded in income tax expense during the six months ended June 30, 2026 and 2025 was \$6,891 and \$6,036, respectively.

15. RELATED PARTY TRANSACTIONS

The Company had the following related party transactions:

Nature of transaction	Three Months Ended June 30,		Six Months Ended June 30,		As of	
	2026	2025	2026	2025	June 30, 2026 (unaudited)	December 31, 2025
	Related Party Expense		Related Party Expense		Related Party Payable	
Second Lien Notes - interest expense and principal amount ⁽¹⁾	\$ —	\$ (780)	\$ (747)	\$ (1,447)	\$ —	\$ (25,909)
2024 Term Loan - interest expense and principal amount ⁽¹⁾	\$ —	\$ (489)	\$ (421)	\$ (972)	\$ —	\$ (15,200)
2026 Term Loan - interest expense and principal amount ⁽²⁾	\$ (1,527)	\$ —	\$ (1,611)	\$ —	\$ (49,009)	\$ —

⁽¹⁾ The Second Lien Notes, the 2024 Term Loan payable and the related interest expense include amounts related to the Company's Chief Executive Officer, as well as a significant investor. Both the Second Lien Notes and the 2024 Term Loan were settled in March 2026. Refer to Note 8 - Debt for more information.

⁽²⁾ The 2026 Term Loan, together with the related interest expense, include amounts related to an entity controlled by the Company's Chief Executive Officer, as well as a significant investor. Refer to Note 8 - Debt for more information.

16. COMMITMENTS AND CONTINGENCIES
Contingencies

Although the possession, cultivation and distribution of cannabis for medical and recreational use is permitted in certain states, cannabis is generally classified as a Schedule I controlled substance under the U.S. Controlled Substances Act and its use remains a violation of federal law. Effective April 28, 2026, Food and Drug Administration ("FDA") approved drug products containing cannabis, as well as cannabis produced, distributed and dispensed under qualifying state medical marijuana licenses, are classified as a Schedule III controlled substance; however, there is uncertainty governing the application of this newly bifurcated treatment at the federal level. The Company's operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. While management believes that the Company is in material compliance with applicable local and state regulations as of June 30, 2026, marijuana regulations continue to evolve and are subject to differing interpretations. As a result, the Company could be subject to regulatory fines, penalties or restrictions at any time. Since the federal law status of the use of cannabis preempts state laws that legalize its use, strict enforcement of federal law regarding cannabis would likely result in the Company's inability to proceed with the Company's business plans. In addition, the Company's assets, including real property, cash and cash equivalents, equipment, inventory and other goods, could be subject to asset forfeiture because cannabis is still federally illegal.

Refer to Note 14 - Income Taxes for certain tax-related contingencies.

JUSHI HOLDINGS INC.**Notes to the Unaudited Condensed Consolidated Financial Statements***(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)***Claims and Litigation**

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of June 30, 2026, except as set forth below, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the Company's financial results. There are also no proceedings in which any of the Company's directors, officers or affiliates is an adverse party or has a material interest adverse to the Company's interest.

MJ's Market Matter

On March 31, 2023, MJ's Market, Inc. ("MJ's") filed a complaint in federal district court in Massachusetts adverse to Jushi Holdings Inc. and certain of its subsidiaries, including Jushi MA, Inc., Jushi Inc. and Nature's Remedy of Massachusetts, as well as the former owners and affiliates of Nature's Remedy of Massachusetts (the "Complaint"). The Complaint centrally claims that the structure of the Nature's Remedy of Massachusetts transaction providing for increased purchase price consideration if there is no competing dispensary within 2,500 foot radius by certain time periods, and the Company's filing with the Massachusetts Superior Court an appeal of the Town of Tyngsborough's decision to approve MJ's facility in contradiction of its own zoning bylaws are violations of the Sherman Antitrust Act, Massachusetts Antitrust Act, and Massachusetts Consumer Protection Act, as well as interference with contractual relations and abuse of process. MJ is seeking legal and equitable remedies including compensatory and other damages. On February 5, 2025, the court denied the defendants' motion to dismiss, and the parties to the Complaint are in discovery. The Company disputes such allegations, believes it has substantial defenses and is vigorously defending against the Complaint.

Sammartino Matter

On February 28, 2023, the Company informed Sammartino, the former owner of Nature's Remedy and certain of its affiliates, that Sammartino had breached several provisions of the Merger and Membership Interest Purchase Agreement between the Company, Sammartino and certain other parties thereto (as amended, the "MIPA") and/or fraudulently induced the Company to enter into, and not terminate, the MIPA. As a consequence of these breaches and the fraudulent inducement, the Company informed Sammartino that the Company had incurred significant damages, and pursuant to the terms of the MIPA the Company had elected to offset these damages against certain promissory notes and shares the Company was to pay and issue, respectively, to Sammartino, and that Sammartino would be required to pay the remainder in cash. On March 13, 2023, Sammartino responded to the Company by alleging various procedural deficiencies with the Company's claim and provided the Company with a notice that the Company was in default of the MIPA for failing to issue certain shares of the Company to Sammartino. On March 21, 2023, Sammartino sent a second notice that the Company was in default of the promissory notes for failing to pay interest pursuant to their specified schedule. On March 23, 2023, the Company sent a second letter to Sammartino disputing each procedural deficiency claimed by Sammartino and disputing that the Company is in default of the MIPA or the promissory notes and that it properly followed the terms of the various agreements in electing to set off the damages.

Pacific Collective Matter

On October 24, 2022, Pacific Collective, LLC ("Pacific Collective") filed a complaint in state court in California against Jushi subsidiaries TGS CC Ventures, LLC ("TGS"), and Jushi Inc. Pacific Collective alleges that the Jushi subsidiaries breached a commercial property lease and lease guaranty and that Pacific Collective is entitled to recover in excess of \$20,000 in damages. TGS believes it lawfully rescinded the lease based on Pacific Collective's failure to purchase the property that was the subject of the lease and to construct and deliver the building contemplated by the lease and is of the position that no damages are owed to Pacific Collective. The Referee assigned to the matter ruled in favor of and awarded fees and costs to TGS and Jushi. Pacific Collective filed an appeal on July 3, 2024, which remains pending.

JUSHI HOLDINGS INC.**Notes to the Unaudited Condensed Consolidated Financial Statements***(Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)***Commitments**

In addition to the contractual obligations outlined in Note 8 - Debt, the Company has commitments as of June 30, 2026 related to property and construction.

In connection with various license applications, the Company may enter into conditional leases or other property commitments which will be executed if the Company is successful in obtaining the applicable license and/or resolving other contingencies related to the license or application.

In addition, the Company expects to incur capital expenditures for leasehold improvements and construction of buildouts of certain locations, including for properties for which the lease is conditional on obtaining the applicable related license or for which other contingencies exist.

17. FINANCIAL INSTRUMENTS

The following table sets forth the Company's financial assets and liabilities, subject to fair value measurements on a recurring basis, by level within the fair value hierarchy:

	June 30, 2026 (unaudited)	December 31, 2025
Financial liabilities: ⁽¹⁾		
Derivative liabilities ⁽²⁾	\$ 5,962	\$ 8,607
Total financial liabilities	<u>\$ 5,962</u>	<u>\$ 8,607</u>

⁽¹⁾ The Company has no financial assets or liabilities in Level 1 or 2 within the fair value hierarchy as of June 30, 2026 and December 31, 2025, and there were no transfers between hierarchy levels during the six months ended June 30, 2026 or year ended December 31, 2025.

⁽²⁾ Refer to Note 9 - Derivative Liabilities.

The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and certain accrued expenses, and certain other assets and liabilities held at amortized cost, approximate their fair values due to the short-term nature of these instruments. The carrying amounts of the Company's long-term debt (which consists of term loans, mortgage loans and promissory notes) approximate their fair values as the effective interest rates are consistent with market rates. Refer to Note 8 - Debt for more information.

18. SEGMENT INFORMATION

The Company operates a vertically integrated cannabis business in one reportable segment for the cultivation, processing, distribution and sale of cannabis in the U.S. All of the Company's revenues were generated within the U.S., and substantially all long-lived assets are located within the U.S. The accounting policies for the Company's reportable segment are the same as those described in Note 2 in the audited consolidated financial statements for the year ended December 31, 2025, which is included in the 2025 Form 10-K. The chief operating decision maker is the Chief Executive Officer. The chief operating decision maker assesses performance and decides how to allocate resources based on operating results that are reported on the income statement as consolidated net income (loss). The measure of segment assets is reported on the balance sheet as total consolidated assets. Refer to Note 13 - Operating Expenses for significant expenses for the reportable segment.